Inari Medical Appoints Dana G. Mead, Jr. to Board of Directors
October 01 2021 - 8:00AM
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device
company focused on developing products to treat and transform the
lives of patients suffering from venous diseases, today announced
the appointment of Mr. Dana G. Mead, Jr. to its board of directors.
Mr. Mead will serve as a member of the Compensation Committee of
the board.
“We are pleased to welcome Dana as a new independent director to
our board. Mr. Mead’s decades of executive operating experience
leading high growth med tech businesses, will be highly valuable to
Inari as we enter the next phase of our mission to treat and
transform the lives of patients suffering from venous
thromboembolism,” said Bill Hoffman, Inari’s Chief Executive
Officer.
From May 2019 to February 2021, Mr. Mead served as
President and CEO of HeartFlow, Inc., a medical device company
located in Redwood City, CA. From November 2016 to May 2019,
Mr. Mead served as the President and Chief Executive Officer
of Beaver-Visitec International, a medical device company located
in Waltham, MA. Previously, Mr. Mead was a Strategic Advisor
and Partner at Kleiner Perkins Caufield & Byers, a venture
capital firm, having joined the firm in May 2005 where he served
until June 2016. Mr. Mead was at Guidant Corporation, a
cardiovascular medical device company, from 1992 to 2005, most
recently as President, Guidant Vascular Intervention. Since July
2008, Mr. Mead has served as a member of the board of
directors of Inspire Medical Systems, Inc., a NYSE listed medical
technology company. Since February 2010, Mr. Mead has served on the
board of directors of Pulmonx Corporation, a NASDAQ listed medical
device company, and since June 2007 on the board of directors of
Intersect ENT, Inc., a NASDAQ listed medical device company.
Mr. Mead also served on the board of directors of Teladoc,
Inc., a NYSE listed telehealth platform company, from August 2011
to December 2016.
About Inari Medical, Inc.Inari Medical, Inc. is
a medical device company focused on developing products to treat
and transform the lives of patients suffering from venous diseases.
Inari has developed two minimally-invasive, novel catheter-based
mechanical thrombectomy devices that are designed to remove large
clots from large vessels and eliminate the need for thrombolytic
drugs. The company purpose-built its products for the specific
characteristics of the venous system and the treatment of the two
distinct manifestations of venous thromboembolism, or VTE: deep
vein thrombosis and pulmonary embolism. The ClotTriever system is
510(k)-cleared by the FDA and CE Mark approved for the treatment of
deep vein thrombosis. The FlowTriever system is 510(k)-cleared by
the FDA and CE Mark approved for the treatment of pulmonary
embolism and clot in transit in the right atrium.
Investor Contact:Westwicke PartnersCaroline
CornerPhone +1-415-202-5678 caroline.corner@westwicke.com
Inari Medical (NASDAQ:NARI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Inari Medical (NASDAQ:NARI)
Historical Stock Chart
From Sep 2023 to Sep 2024